Risk factor
Strong trading liquidity
Profitability factor
Very strong margins and returns
About
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and...
Company Valuation
From both historical and forecast perspectives, the stock is fairly priced compared to similar stocks. Specifically, the stock is 'cheap' on P/E, neutral on EV/EBITDA, re
Target Price
The average target price of EXEL is 46 and suggests 11% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendation su
Buy
Sell